Promises Kept, Price Paid in Advance: A Clean Beat-and-Raise Meets a Stock That Has Run Through Our Bull Case

Results vs. Consensus

Q3 2026 Scorecard

No basis argument this quarter. July's print produced simultaneous beat and miss headlines because the Street's bar sat on three different treatments of acquired IPR&D. This time the three providers we track sat between $3.73 and $3.77, all below the $3.82 actual, so the print reads as a beat on every basis. The company's own arithmetic is the cleanest: $3.82 plus $0.11 of IPR&D equals $3.93, which is $0.07 above the $3.84 to $3.88 guide set in July. The revenue beat against the Street was narrower than in Q2 (roughly +0.4% at the middle of the range against +1.1%), but the beat against management's own guide was the familiar $0.2B.

Year-Over-Year Comparison (Q3)

The table has the same shape as in our Q2 note, with two differences that matter. The ex-IPR&D operating margin is now expanding at a meaningful rate rather than drifting, and oncology has crossed back above zero. Skyrizi and Rinvoq together added $1.590B of growth against a total company increase of $1.628B, so the two products still account for roughly 98% of the company's growth. Neuroscience added about $550M more. Humira's $310M decline, aesthetics' $17M decline and a roughly $200M decline across the mature products outside the four named portfolios absorbed most of the rest. The prior-year neuroscience figure reflects the current product grouping, which differs by a few million dollars from the figure first reported a year ago.

Sequential (QoQ) Context

Two sequential rows deserve a second look. Rinvoq grew faster than Skyrizi quarter on quarter (+7.2% against +4.9%), consistent with management's comment that Rinvoq momentum is strongest in rheumatoid arthritis and inflammatory bowel disease. Vraylar was flat sequentially at $1.068B and decelerated to +14.3% year over year from +18.9% in Q2, a quarter before its Medicare negotiated price takes effect in 2027. The aesthetics decline of 8.3% sequentially is partly seasonal (the same quarter fell 6.7% sequentially a year ago), but it is the steeper of the two. Vyalev's sequential growth slowed to 11.7% from 27.4% in Q2, which is what a launch curve looks like as it matures, and management still expects it to exceed $1B this year.

First Nine Months of 2026

The quarterly figures sum exactly to the nine-month income statement: $31.992B of first-half revenue plus $17.404B equals $49.396B, and $6.30 plus $3.82 equals $10.12 of adjusted EPS. On the clean ex-IPR&D basis the company has grown earnings 15.7% through nine months on 10% operational revenue growth. That is the best nine-month earnings print in our coverage window, and it is the number the 2026 guide now rests on. Aesthetics' nine-month operational growth has slipped to 0.7%, down from 1.9% at the half.

Quality of Beat

Revenue. The beat is organic, with FX a 0.2-point drag rather than a help, and it is concentrated exactly where it was in July. Skyrizi and Rinvoq added $1.590B year over year, neuroscience about $550M, and oncology a small $14M. The Street beat was narrow, between $0.03B and $0.10B, so the revenue story this quarter is less about the size of the beat than its composition: nine products grew double digits, and the one thesis-relevant line that went the wrong way was aesthetics.

Margins. Adjusted gross margin of 85.1% was up about 120 basis points on mix, as the two highest-margin immunology franchises keep growing faster than the company. Adjusted SG&A fell to 21.2% of revenue from 21.6% and adjusted R&D to 13.9% from 14.3%, so both expense lines produced leverage, which they did not in Q2. The full-year guide of about 46.7% (including about 1.8 points of IPR&D, so roughly 48.5% before it) implies a Q4 adjusted operating margin near 48%, lower than Q3's 49.9% ex-IPR&D, because the implied Q4 R&D of about $2.79B is roughly $370M above Q3's $2.425B as Apogee programs and new Phase 3 starts come on.

EPS. Ex-IPR&D EPS rose $0.57, from $3.36 to $3.93. Our estimate of the tax contribution is about $0.08: the effective rate on ex-IPR&D earnings fell from roughly 15.2% to 13.4%. Adjusted net interest expense rose 3.1% to $688M, and the diluted share count was flat at 1,772M. Ex-IPR&D pre-tax earnings grew 14.5%, which is the cleanest measure of the operating quarter, and it is consistent with the full-year ex-IPR&D growth rate of about 15% the guide now implies.

Segment Performance

Therapeutic-Area Revenue Mix

The four named portfolios total $15.426B. The "all other products" row is the residual to the income-statement total and includes the disclosed Other Key Products line plus products the company does not break out.

Geographic Split

The geographic cut changes the aesthetics read from July. In Q2 the franchise's flat headline was a shrinking U.S. business (−4.4%) averaged with a growing international one (+5.0% operational). This quarter the U.S. decline narrowed to 2.3%, but international turned negative at −1.0% operational, so the overseas cushion that made Q2 look contained has gone. Elsewhere the pattern held: U.S. immunology grew 16.8% as Humira's U.S. line fell 39.9%, and U.S. oncology fell 5.7% on Imbruvica's 33.0% U.S. decline while international oncology grew 11.4% operationally.

Immunology: two products, 48.7% of revenue, two competitive entries absorbed

Immunology delivered $9.165B, up 16.3% reported and 16.6% operationally, an acceleration from Q2's +14.6% operational. Skyrizi grew 22.9% operationally to $5.776B and Rinvoq 24.3% operationally to $2.706B. Together they reached $8.482B, 48.7% of company revenue against 43.7% a year ago and 47.3% in Q2. Humira fell 31.2% to $683M and is now 3.9% of revenue. Management's framing of the year was the most useful single disclosure on the competitive question: of roughly $6B of combined 2026 growth, about $3B is coming from inflammatory bowel disease and about $2B from Skyrizi in psoriatic disease, the two markets where competitors launched.

"Recent oral competition is not having a substantive impact on our in-play patient share with Skyrizi continuing to capture roughly 1 out of every 2 new or switching psoriasis patients." — Jeffrey Stewart, Chief Commercial Officer

The subcutaneous induction approval in Crohn's disease arrived in the quarter, along with a label change that leaves tuberculosis screening to physician judgment. Management guided to a share acceleration in Crohn's in the first half of 2027 once contract access is in place, and raised the Skyrizi full-year guide a third time to about $21.8B and Rinvoq to about $10.3B.

Assessment: The load-bearing wall got stronger. Growth accelerated at a larger base, the competitive entries in both of the franchise's largest markets are now visible in the numbers and have not dented them, and the next catalyst is approved rather than pending. The full-year guides imply Q4 Skyrizi of about $6.04B (+20.6%) and Rinvoq of about $2.95B (+24.3%), which is a continuation rather than a stretch. Concentration remains the other side of this coin: at 48.7% of revenue and 98% of growth, any wobble in these two lines is the whole story.

Neuroscience: still the second engine, with a slower Parkinson's on-ramp

Neuroscience grew 19.4% reported to $3.389B. Botox Therapeutic grew 9.8% to $1.080B, Vraylar 14.3% to $1.068B, Ubrelvy 26.9% to $449M and Qulipta 38.2% to $398M. Vyalev reached $286M. The full-year neuroscience guide rose $300M to about $13.0B, with Vraylar at about $4.2B, Botox Therapeutic at about $4.2B and the two oral migraine drugs at about $3.1B.

"Sales for Juvmo are expected to ramp gradually over the next several quarters as we work to establish commercial and Medicare coverage, which is expected to be more broadly available starting in 2028." — Jeffrey Stewart, Chief Commercial Officer

Juvmo, the once-daily D1/D5 agonist, was approved in the quarter. Management sized the Parkinson's franchise, Juvmo plus Vyalev and Duopa, at more than $5B of combined peak sales, and said early demand through medical-exception channels has exceeded its expectations.

Assessment: The growth rate held near 20% and the full-year raise was the largest of any therapeutic area. Two details temper it. Vraylar, the largest neuroscience product, was flat sequentially and decelerated four points year over year a quarter before its Medicare negotiated price arrives in 2027. And the oral Parkinson's launch, which July described as "modest at first," now has broad Medicare coverage in 2028. The Parkinson's franchise is still the most credible unmodeled medium-term growth in the portfolio. It is a 2028 contributor, not a 2027 one.

Oncology: back above zero, with a guide that does not assume it stays there

Oncology grew 0.8% reported and 0.9% operationally to $1.696B, its first growth quarter after four consecutive declines. Venclexta grew 10.7% to $803M, Elahere 31.0% to $224M and Epkinly 57.7% to $108M. Imbruvica fell 26.1% to $522M on IRA pricing and competition. The rest of oncology added $198M against Imbruvica's $184M decline, the crossover our Q2 note described as arriving "sometime in 2027 without anything new happening." It arrived two quarters early.

"I'm also very excited for our developing portfolio in hematology following positive data for both etentamig in multiple myeloma and Epkinly in frontline DLBCL. We anticipate their potential approvals will be an important catalyst for next year and immediately supported by our existing commercial resources, including a substantial heme sales force and medical affairs team." — Jeffrey Stewart, Chief Commercial Officer

The full-year oncology guide rose to about $6.6B, with Venclexta higher at about $3.1B and Imbruvica lower at about $2.1B. Taken literally, that implies Q4 oncology of about $1.62B, roughly 2.5% below Q4 2025's $1.664B, though the rounding on a $6.6B figure is wide enough to cover a flat quarter.

Assessment: The bear point is easing on schedule, early. The pipeline news behind it is substantive: an etentamig filing with a 2027 decision, a positive Phase 3 for Epkinly with chemotherapy in newly diagnosed DLBCL, and two breakthrough designations for Temab-A. Two cautions. The company's own full-year number does not assume growth persists into Q4. And Epkinly's U.S. and Japan revenue is booked as a profit share, so a large frontline launch shows up smaller on the revenue line than the clinical result suggests.

Aesthetics: worse operationally, better in tone

Aesthetics delivered $1.176B, down 1.4% reported and 1.8% operationally, a deeper decline than Q2's −0.9%. Botox Cosmetic improved slightly to +4.1% operational at $669M. Juvederm deteriorated to −11.8% operational at $222M from −6.6%, and other aesthetics fell 6.0%. Management's language moved the other way from the numbers.

"While economic uncertainty and lower consumer confidence have pressured the aesthetics category over the last several quarters, we are starting to see signs of stability." — Jeffrey Stewart, Chief Commercial Officer

The forward items did improve. The fast-acting short-duration toxin now has a U.S. resubmission planned before year-end and a decision expected in mid-2027, the first date in two quarters. A masseter-prominence filing for Botox Cosmetic was accepted for review, which would be its fifth aesthetic indication. And the full-year aesthetics outlook was held at about $5.0B, with Botox Cosmetic raised to about $2.8B.

Assessment: The trough is still unproven, and the arithmetic of the guide is now the most interesting thing about it. Against $3.644B through nine months, an unchanged ~$5.0B implies Q4 aesthetics of about $1.36B, roughly 5% above Q4 2025's $1.286B, after a 1.4% decline in Q3. Even allowing for rounding on a figure stated to one decimal, the guide assumes the franchise returns to growth next quarter. We would rather see that than infer it. At 6.8% of revenue aesthetics will not set the stock, but it was one of the three triggers behind our April upgrade, and it has now missed in two consecutive quarters.

Other products: the shrinking 11%

Products outside the four named portfolios totaled $1.978B, about 9% below a year ago and now 11.4% of revenue. Within the disclosed Other Key Products line of $965M, Creon fell 2.2% to $361M and Mavyret 15.1% to $265M, while Linzess grew 4.2% to $339M.

Assessment: Unchanged from July and still not a thesis item. It is part of why 16.6% immunology growth and 19.5% neuroscience growth produce a 10.5% company growth rate, and it will keep doing that.

Key Topics & Management Commentary

Overall Management Tone: Confident and noticeably comparative: management ranked its 2026 growth second among peers, called two pipeline assets significantly undercalled in Street models, and promised top-tier growth in 2027 without a number. Q&A was almost entirely pipeline and policy, and no question touched the quarter's margins, the Q4 EPS guide sitting below the Street, or the aesthetics revenue decline. Against Q2, when the call defended a deal and said nothing about capital returns, the posture moved to arguing for the multiple, which is what a management team does once the valuation has become the debate.

1. The Earnings Base Moved Up for the First Time Since April

The as-published 2026 range went from $13.87 to $14.07 in July to $13.95 to $13.99 now, an unchanged $13.97 midpoint on a narrower range. That headline hides a genuine raise. The July range excluded IPR&D beyond Q2; folding in Q3's $0.11 restates it to $13.76 to $13.96, and from there the midpoint rose $0.11. On a like-for-like ex-IPR&D basis the midpoint is now about $14.66, against $14.47 at the initial February guide, $14.59 in April and $14.55 in July.

"We are raising our full year adjusted earnings per share guidance range by $0.11 at the midpoint to between $13.95 and $13.99. This guidance does not include acquired IPR&D expense that may be incurred beyond the third quarter." — Scott Reents, Chief Financial Officer

The $0.11 splits into the $0.07 Q3 beat and about $0.04 added to the implied Q4. Management did not restate the $0.14 of 2026 Apogee dilution it gave in July, so we assume it is unchanged.

Assessment: This is the first quarter since April in which the ex-IPR&D earnings base moved up rather than sideways, and it moved up by about 0.8%. That is the right direction and a small distance. It is also the comparison that matters for the rating: the stock rose 17.5% over the same three months.

2. Skyrizi and Rinvoq: $6B of Growth Through Two Competitive Entries

The CEO used the first question of the call to decompose the year's growth, and the decomposition is the strongest available answer to the competitive bear case. Of about $6B of combined Skyrizi and Rinvoq growth in 2026, roughly half is in inflammatory bowel disease and a third is Skyrizi in psoriatic disease, both markets with new entrants.

"When I look at Skyrizi and Rinvoq, they're delivering incredible growth of $6 billion combined this year despite already being on the market for 8 years and with more competition. If you think about where that growth is coming from, that $6 billion, $3 billion of it is in IBD across Rinvoq and Skyrizi with obviously a competitive entry in that space. $2 billion of that growth is in Skyrizi psoriatic with the competitive entry in that space as well." — Robert A. Michael, Chairman & CEO

Management also said Skyrizi still takes about half of new patient starts in IBD and roughly one in two new or switching psoriasis patients, and pointed to a head-to-head readout against the leading integrin therapy in ulcerative colitis as a 2027 catalyst.

Assessment: Two quarters after the oral IL-23 launch, the data say what management said they would. This is a full confirmation of Bull 1 at a larger base. It does not change the valuation question, because the market has been underwriting exactly this outcome since the spring.

3. Skyrizi Subcutaneous Induction: Approved, With the Ramp in the First Half of 2027

The approval was the top item on our Q2 note's list of commitments. Management described the induction data as numerically higher than its own intravenous induction and strongest in patients new to advanced therapy, where it cited 60% endoscopic response, 43% endoscopic remission and 74% clinical remission at week 16.

"Now while access typically takes a couple of months to ramp, our commercial and medical teams have already hit the ground running, and we expect the subcu induction will accelerate our new patient share in Crohn's over the next several quarters." — Jeffrey Stewart, Chief Commercial Officer

Assessment: Delivered, and on the timeline management set in July: the effect shows up in 2027, with roughly 60 days to full access and a "pretty rapid share acceleration" into the second quarter. This is a 2027 revenue catalyst that we and, we suspect, the Street already carry in the 2027 numbers.

4. 2027: "Top-Tier Growth," Vraylar's IRA Price, and No Number Until February

Asked for the pushes and pulls in 2027, management offered one explicit headwind and one qualitative promise. The headwind is Vraylar's Medicare negotiated price, which begins in 2027. The promise is growth that ranks near the top of the peer group again.

"Our sales and earnings growth in 2026 will be the second highest relative to our peers. And we expect to deliver top-tier growth again next year." — Robert A. Michael, Chairman & CEO

The CEO added that "many of the sell-side models have appeared to have modeled" the Vraylar price, and that formal 2027 guidance will come on the Q4 call as usual. The Juvmo ramp is described as more significant in 2028 and beyond.

Assessment: The 2027 bridge has three identifiable drags the stock is not discussing: Vraylar's IRA price on a roughly $4.2B product, a full year of Apogee financing and development spending, and a Humira line still falling about 30%. The tailwinds are real (subcutaneous induction, two Rinvoq dermatology launches, etentamig and Epkinly). A 2027 Street EPS figure of about $16.28 implies roughly 11% growth from the ~$14.66 ex-IPR&D 2026 base. That is achievable, and at 18.1x it also has to be achieved.

5. Neuroscience: $13B for 2026, and the Parkinson's Franchise Pushed to 2028

Neuroscience got the largest full-year raise of any area, $300M to about $13.0B. Juvmo was approved, and management described physician reaction as strong, with low rates of the impulse-control and sleep-attack side effects that limited older dopamine agonists.

"Along with Vyalev/Duopa, we expect our Parkinson's therapies to collectively deliver peak sales of more than $5 billion." — Robert A. Michael, Chairman & CEO

The pipeline additions were mostly psychiatric: an emraclidine Phase 2 restart at 150mg, five times the highest dose in the two earlier pivotal trials, a bretisilocin Phase 3 start in major depression, and a positive Phase 3 for Qulipta in menstrual migraine with a U.S. filing for Ubrelvy in the same indication possible in early 2027.

Assessment: Bull 3 holds. The franchise grew at nearly 20%, and the "three $5B-plus franchises" framing now has an approved product in each. The Medicare timing on Juvmo is the one material slippage on the call, and the emraclidine restart is a second attempt at an asset whose two earlier pivotal trials missed. We treat it as an option with low current value.

6. Oncology Inflects, and Management Says the Street Is Missing Two Multibillion-Dollar Assets

The hematology pipeline produced the quarter's two most consequential data events: positive Phase 3 data and a U.S. filing for etentamig in relapsed myeloma, with approval expected in 2027, and a 51% reduction in the risk of progression or death for Epkinly with R-CHOP in newly diagnosed DLBCL, with filings early next year. In solid tumors, Temab-A received two breakthrough designations and the PD-1/VEGF bispecific entered Phase 3 in lung cancer.

"We've mentioned etentamig. It's a multibillion-dollar opportunity that is significantly undercalled in many Street models. I would add Temab-A to that as well, similar a multibillion-dollar opportunity, significantly undercalled in many Street models." — Robert A. Michael, Chairman & CEO

Assessment: Bear 3 is easing, and the oncology pipeline is now the part of the story with the most new information. We take the data at face value and the "undercalled" claim with caution. Management is making the argument for the multiple, which is its job. Neither asset generates meaningful revenue before 2028, and the myeloma bispecific field already has several approved competitors.

7. Aesthetics: A Resubmission Date, a Better Tone, and a Worse Number

The short-duration toxin finally has a U.S. timeline. Management said the complete response letter concerned manufacturing data rather than safety or efficacy, that the resubmission will go in before year-end, and that it expects a six-month review.

"We continue to work closely with the FDA to resolve outstanding matters related to the complete response letter for Boey, resubmission to the FDA is anticipated before the end of this year, with a regulatory decision expected in mid-2027." — Roopal Thakkar, EVP, R&D and Chief Scientific Officer

Management also started a Phase 2 combining the new toxin with Botox in glabellar lines.

Assessment: One of the open items from our Q2 note closed. The other did not: the franchise declined faster, fillers fell 11.8%, and international aesthetics turned negative. "Starting to see signs of stability" is a forecast, and the full-year guide quietly depends on it being right in Q4. Bear 2 stays EMERGING.

8. Apogee Closed: Eight Phase 3 Programs, Still No Accretion Year

The acquisition closed in the quarter. The lead asset's Phase 2 Part B data at EADV showed all three dose regimens meeting the primary endpoint in atopic dermatitis, and the Phase 3 program starts later this year. Management outlined a development plan that runs well into the next decade.

"...imagining as those move forward, 8 distinct Phase III programs that would be reading out in late '29 across the -- into the mid-2030s. So quite a bit to keep an eye on in immunology." — Roopal Thakkar, EVP, R&D and Chief Scientific Officer

Assessment: The strategy is coherent and the timeline is long. For the second quarter running, management gave no year in which the deal turns accretive and no peak-sales figure for zumilokibart, only that it is "upside to the Street." Eight Phase 3 programs reading out from late 2029 is a 2030s value driver. Its near-term cost shows up in Q4's implied R&D step-up and in 2027.

9. Policy: A Botox Court Win, a Vraylar Price in 2027, and a 340B Pilot

Three policy items surfaced, more than on the July call. On Botox, a federal district court ruled for AbbVie the day before the call in its challenge arguing that the product, which contains a plasma-derived ingredient, is not eligible for Medicare price negotiation. On Vraylar, the negotiated price starts in 2027. And AbbVie is participating in a 340B rebate pilot next year for Imbruvica, Linzess and Vraylar.

"Look, we feel the IRA is very clear that products derived from human blood or plasma are not eligible for selection... and a Federal District Court just yesterday ruled in our favor. Now that ruling is subject to appeal by the government. So we'll have to wait to see if there are any more proceedings. But in the meantime, we would not expect a price to be published while this plays out." — Robert A. Michael, Chairman & CEO

On the 340B pilot, the CEO said it is "too early to call a financial impact." Tariffs and Section 232 were not mentioned for the second consecutive call.

Assessment: The Botox ruling is the most valuable non-financial event of the quarter. It removes, for now, a future price-setting overhang on a roughly $4.2B therapeutic franchise, and it is subject to appeal. We give it partial credit in fair value rather than full credit. Bear 4 stays CONTAINED, with a better mix of outcomes than in July.

10. Capital Allocation Returns to the Script

In July the words "dividend," "free cash flow" and "capital allocation" did not appear on the call. This quarter the CFO closed with all three, and the board raised the quarterly dividend 5.2% to $1.82, payable from February 2027.

"Our cash balance at the end of September was $10.8 billion, and we generated approximately $14 billion of free cash flow in the first 9 months of the year, which includes nearly $2.7 billion of Skyrizi royalty payments." — Scott Reents, Chief Financial Officer

The CFO reaffirmed the two-times net-leverage target "over the next 2 to 3 years" after the Apogee close. The CEO said future deals are more likely to be bolt-ons than a transformational acquisition, with obesity named as an area to expand.

Assessment: Bear 5 moves from EMERGING to CONTAINED. The cash generation is large, the dividend kept growing at roughly last year's pace (5.2% against 5.5%), and management explicitly ruled out another Allergan-scale deal. At $294.89 the forward yield on the new rate is 2.47%, down from 2.76% at the $250.94 price of our Q2 note, so the income part of the return keeps shrinking as the price rises.

11. The Immunology Pipeline Behind Skyrizi: Lutikizumab, Combinations, and a Rinvoq HS Readout

Lutikizumab, an IL-1α/β antibody, met its Phase 3 primary endpoint in hidradenitis suppurativa, with filings planned for the second half of 2027. The Skyrizi combination with ABBV-382 roughly doubled endoscopic remission at week 24 against either monotherapy in Crohn's, and a large Phase 2b of two combinations is underway. Rinvoq's own HS Phase 3 reads out near year-end.

"HiSCR 75, which is a rigorous bar for defining clinical response was achieved by 31% of lutikizumab patients." — Roopal Thakkar, EVP, R&D and Chief Scientific Officer

Assessment: Management gave the active-arm response rate but not the placebo rate, so the 31% is hard to judge on its own, and it declined to frame expectations for the Rinvoq HS readout. The combination data are the more strategically important item, because they are AbbVie's answer to what follows Skyrizi in IBD in the 2030s. The Phase 3 start could come as early as late 2027, which keeps this a long-dated option.

Guidance & Outlook

The guide now carries more detail than at any point this year, with full-year figures for every therapeutic area and most major products. Management framed the raise as a breadth story, with nine products growing double digits and increases in immunology, neuroscience and oncology.

Implied Q4. Revenue of about $18.4B is +10.7% against Q4 2025's $16.618B, consistent with the nine-month rate. The product guides imply Q4 Skyrizi of about $6.04B (+20.6%), Rinvoq of about $2.95B (+24.3%), neuroscience of about $3.51B (+18.5%), oncology of about $1.62B (about −2.5%) and aesthetics of about $1.36B (about +5%). The EPS midpoint of $3.85 compares with $3.42 ex-IPR&D in Q4 2025, +12.6%, a deceleration from Q3's +17.0% that is explained by the implied R&D step-up of roughly $370M. The aesthetics figure is the one we would not rely on.

Street at. Before the print, the Street carried Q4 EPS of about $3.91 and full-year EPS of about $13.92. The new full-year midpoint of $13.97 sits above that because Q3 beat, but the Q4 guide midpoint sits about $0.06 below the Street's Q4 number, on a basis that excludes any Q4 IPR&D the Street may already allow for. For 2027 the Street sits at about $16.28 and $73.6B of revenue.

Guidance style. Unchanged and predictable. Across our coverage, management has raised revenue guidance steadily, raised the operating EPS assumption most quarters, and refused to forecast deal spending. Q3 beat management's own revenue expectations by about $0.2B, after about $0.3B in each of Q1 and Q2. On that pattern the Q4 EPS guide is probably beatable by a few cents, and the 2027 guide in February will start from a deliberately reachable level.

Analyst Q&A Highlights

What to model for 2027 before the formal guide

The call opened with a request for the moving parts of next year, ahead of formal guidance on the Q4 call. Management answered with a peer ranking, a qualitative promise of top-tier growth, a list of immunology catalysts, and one explicit headwind it asked analysts to model.

Q: "Maybe if I could just as I know you're not giving formal guidance for next year yet, but if I could just ask about -- as we think about updating our models today, any sort of key pushes and pulls as we think about next year in terms of dynamics to keep in mind?"
— Vamil Divan, Guggenheim Securities

A: "And then I would also keep in mind that the IRA price for Vraylar will begin in 2027, so you should be modeling that in as well, although I'd say many of the sell-side models have appeared to have modeled that in. But clearly, I mean, we have a lot of momentum across our business to drive strong top-tier growth again next year."
— Robert A. Michael, Chairman & CEO

Assessment: A useful answer, and a deliberately incomplete one. Management named one 2027 headwind without sizing it, and left the full-year cost of the Apogee financing and development plan unsaid. "Top-tier" is a ranking, not a growth rate. The 2027 guide in February is now the most important single input to the rating.

How fast subcutaneous induction moves share in Crohn's

The commercial question on the new approval was how quickly it changes share dynamics against the main IBD competitor. Management gave a specific access timeline and a quarter in which it expects the acceleration to be visible.

Q: "Can you just help frame out the opportunity here? I guess, specifically, how are you thinking about market share dynamics going forward? And I guess, how quickly do you think that could play through as you think about just kind of the ramp of Skyrizi from here?"
— Christopher Schott, JPMorgan

A: "Now in terms of timing as to when we'd see that, it will take us probably 60 days, maybe a little bit longer to get full access. That's just the normal cycle of the approval of something like this with our contracts. So certainly the first part of the year into the second quarter, we anticipate a pretty rapid share acceleration there."
— Jeffrey Stewart, Chief Commercial Officer

Assessment: Specific and checkable, which is how this team usually answers commercial questions. It puts a measurable test on the Q1 and Q2 2027 prints. With in-play share described as roughly 50-50 against the main competitor today, the read-through to watch is whether Crohn's new-patient share moves visibly above that by mid-2027.

Which pipeline assets the Street is missing

Invited to name underappreciated assets, three executives answered in turn, and the answers amounted to a case for a higher long-term multiple. The CEO named two oncology assets as multibillion-dollar opportunities and said the neuroscience peaks and the lead Apogee asset are also above consensus.

Q: "And then the other thing I want to ask you is that you have a lot of potentially best-in-class assets in your pipeline. Maybe if you could highlight to us which one or which ones you're most excited about that you think are underappreciated by the Street."
— Louise Chen, Scotiabank

A: "So as I look at the portfolio, we have -- as we look at longer-term growth in the 2030s, we have a number of upside opportunities that are not yet reflected in Street models."
— Robert A. Michael, Chairman & CEO

Assessment: The most important sentence on the call for the valuation debate, and the hardest to underwrite. Management may be right that etentamig and Temab-A are undercalled, and the data this quarter support both. But every asset named is a 2028-and-later revenue contributor, and a stock at 18x next year's earnings has already moved some way toward paying for upside it cannot yet see in reported numbers.

The toxin resubmission timeline after the complete response letter

The aesthetics question on the call was not about the revenue decline. It asked for the timeline on the fast-acting toxin, the item that had gone two quarters without a U.S. date. Management gave one and characterized the deficiency as chemistry, manufacturing and controls.

Q: "And then on aesthetics, could you just give us an update on TrenibotE following the CRL and your just time lines for resubmission? Just how should we think about that?"
— Trung Huynh, RBC Capital Markets

A: "Recall that the CRL was not due to any particular issues around safety or efficacy it was on CMC assessments. And we're gathering that data for the agency, and we will resubmit at the end of this year, and we anticipate a 6-month review. So we think the middle of next year in the U.S."
— Roopal Thakkar, EVP, R&D and Chief Scientific Officer

Assessment: A commitment our Q2 note asked for, delivered. A manufacturing-only deficiency with a resubmission inside two months and a standard six-month review is a reasonable path to a mid-2027 U.S. launch. It does not address the current franchise decline, which no one asked about.

Deal appetite after Apogee

With the acquisition closed, the question was how large the next deal might be and whether obesity requires an incretin. Management ruled out a transformational deal and repeated that it has the capacity for bolt-ons across early, late and on-market assets.

Q: "I guess, Rob, now that you've integrated Apogee, could you just provide your latest perspective on M&A and business development appetite and how you're thinking about size of potential deals from here?"
— Terence Flynn, Morgan Stanley

A: "We have ample financial capacity to pursue the deals we're interested in. Now I would expect these to be more bolt-on additions versus a large transformational deal like Allergan, and that's because our business already has good breadth."
— Robert A. Michael, Chairman & CEO

Assessment: The clearest capital-allocation statement of the year, and a helpful one for the balance-sheet bear point. A bolt-on strategy is compatible with the two-times leverage target and the dividend growth. It also means acquired IPR&D charges will keep landing inside quarterly adjusted EPS, so the headline-versus-underlying gap that shaped three of our last four notes will not go away.

Botox and the IRA: the court ruling and what happens to the price

A two-part question asked what to expect for the negotiated Botox price and the litigation. Management answered the litigation half with news, a favorable district court ruling the day before, and said it does not expect a price to be published while the case continues.

Q: "Second question is, what should be our expectation for Botox IRA pricing, both in percentage as well as issues revolving around the litigation. Presumably, AbbVie already knows the discount. So what can you tell us?"
— Steve Scala, TD Cowen

A: "Now that ruling is subject to appeal by the government. So we'll have to wait to see if there are any more proceedings. But in the meantime, we would not expect a price to be published while this plays out."
— Robert A. Michael, Chairman & CEO

Assessment: The analyst's premise, that the company already knows the discount, went unanswered, and the percentage half of the question got no figure. That is understandable while litigation continues. The ruling is a genuine positive. Its value depends on an appeal we cannot handicap, so we count it as partial credit.

How large the Parkinson's oral can become, and when

The question asked where the new Parkinson's oral will be positioned and what could surprise to the upside. Management described strong early physician reaction and demand through medical exceptions, and confirmed the 2027 Medicare window has been missed.

Q: "But what could be a surprise for us from the upside point of view? How should -- like what -- where are you positioning it? And what is the feedback you are getting so far from the physicians as you are launching this product?"
— Mohit Bansal, Wells Fargo

A: "So in terms of upside, we know that we've missed sort of the Medicare window for '27. We'd love to be able to sort of see if we can get some early adds, that's sort of speculative at this point. But we are very, very encouraged at the initial market reaction that we're seeing."
— Jeffrey Stewart, Chief Commercial Officer

Assessment: Candid. In July the launch was "modest at first" because of formulary timing; now Medicare access is broadly a 2028 event. The clinical profile appears to be resonating, but in a disease with a heavily Medicare population, 2027 revenue from this product will be small. This is a delay, not a problem with the asset.

How big the new Rinvoq dermatology markets are today

The last question asked whether Rinvoq will be first-line in vitiligo and alopecia areata and how large those markets are. Management said the current markets are small, the patient populations are large, and AbbVie will have to build the category.

Q: "So with the new indications for Rinvoq in vitiligo and alopecia areata, will it be positioned as first line for both of those conditions?"
— Gary Nachman, Canaccord Genuity

A: "So both of these markets are very, very small right now. I mean, if you look at the sales, they're in the small hundreds of millions of dollars. But if you look at their prevalence, they're quite high."
— Jeffrey Stewart, Chief Commercial Officer

Assessment: An honest framing of a category-creation launch. A near-$2B combined peak from markets currently worth a few hundred million dollars requires the company to build the market, with field-force expansion and consumer activation, and that takes years. Credible peak, slow ramp, consistent with almost every catalyst on this call.

What They're NOT Saying

1. No size for the 2027 Vraylar IRA effect. Management asked analysts to model the negotiated price and said most already have, but did not quantify the Medicare exposure or the expected revenue effect on a roughly $4.2B product. The company has the number; it chose not to give it.
2. No full-year cost of Apogee for 2027, and still no accretion year or peak-sales figure. July's $0.14 of 2026 dilution was not restated after the close, and the 2027 interest and development cost was not framed. Zumilokibart was called "upside to the Street" without a number, the second quarter running.
3. No explanation of the aesthetics guide arithmetic. An unchanged ~$5.0B full-year figure implies Q4 aesthetics of about $1.36B, roughly 5% growth, after a 1.4% decline in Q3. The call offered "signs of stability" but not the Q4 bridge, and nobody asked about international aesthetics turning negative.
4. No comment on the Q4 EPS guide sitting below the Street. The $3.83 to $3.87 range sits about $0.06 under the pre-print Street at the midpoint, and the full-year R&D and SG&A guides imply a Q4 spending step-up of roughly $370M and $150M. Management did not discuss the Q4 cost ramp.
5. No framing for the Rinvoq HS readout. Asked whether to expect a placebo-adjusted benefit closer to 10% or 25% on the primary endpoint, management said "it's difficult to know" and redirected to pain, flares and quality of life. That is a hedge ahead of a year-end readout that is a 2027-2028 revenue item.
6. No tariff, Section 232 or most-favored-nation commentary for the second consecutive call. Policy discussion this quarter was entirely IRA and 340B. The trade-policy overhang that ran through 2025 has not been resolved on the call; it has stopped being discussed.
7. No separate peak-sales figure for Juvmo. The more-than-$5B figure covers the whole Parkinson's franchise, including the already-launched Vyalev and Duopa. With Medicare coverage now a 2028 event, the absence of a standalone figure makes the oral launch harder to model.

Market Reaction

• Pre-print setup: ABBV closed at $290.79 on October 29, 2026, the day before the before-open print and its highest close of the past 52 weeks (closing range $197.38 to $290.79). The stock entered the quarter up 27.3% year to date (from $228.49 at 2025 year-end), up 27.4% over the trailing twelve months (from $228.20) and up 11.2% over the trailing thirty days (from $261.59 on September 30). The S&P 500 was up 12.8% year to date. At $290.79 the stock traded at about 20.0x the then-standing ex-IPR&D 2026 midpoint of $14.55, the most expensive level in our coverage window.
• Reaction session (October 30, before-open print): the stock opened at $292.00, up 0.4%, traded a $291.01 to $298.74 range (up 0.1% to up 2.7%), and closed at $294.89, up 1.4% or $4.10. Volume was 6.9M shares against a 4.8M thirty-day average, or 1.4 times normal.
• Peer and sector context: the S&P 500 fell 1.8% on the session while the health-care sector ETF rose 0.45%. Seven large-cap pharma and biotech peers rose a median 1.9%, in a range from −0.7% to +3.2%. ABBV outperformed the index by about 3.2 points and the sector ETF by about 1.0 point, and lagged the median large-cap peer by about 0.5 point.
• Since our last note: from the $250.94 close on July 31, the price at which our Q2 note downgraded to Hold, ABBV has risen 17.5% (18.2% with the October dividend). Over the same period the S&P 500 rose 1.2% and the health-care sector ETF 13.7%. October alone added 12.7% to ABBV and 9.8% to the sector ETF.

The reaction is a sector story first. On a day when the broad market fell nearly 2%, large-cap pharma rose almost across the board, extending a month-long rotation into defensive groups. ABBV's 1.4% gain on a beat, a raise and a dividend increase was slightly less than the typical peer's gain on the same day. The stock touched $298.74, up 2.7%, and gave back half of that by the close on above-average volume. A stock that has already priced its good news tends to trade like this: the print gives buyers no new reason, and sellers use the strength.

The three-month picture is the more important one for the rating, and it is not flattering to our Q2 call. We moved to Hold at $250.94 on the argument that the price had caught up with the business. Since then the business delivered roughly what we expected (a 0.8% rise in the ex-IPR&D earnings base and a handful of approvals), and the stock returned 18.2% against an index up about 1%. The S&P comparison makes our Hold look badly wrong. The sector comparison shows why: about 13.7 points of that move came with the whole health-care group, and ABBV beat the sector by about 3.8 points. That is a rotation into the group that lifted a good stock with it, not a re-rating of AbbVie in particular.

That distinction is the core of our view. Sector rotations can run for a long time, and we are not forecasting when this one ends. But the Hold was a valuation call, and its premise was that the multiple was fair at about 17x 2026 ex-IPR&D earnings. The multiple is now about 20x on that same basis, after a quarter that moved the earnings base less than 1%. Either the fair multiple for this business rose by three turns in three months, or the price has run ahead of it. We think the second, and we would rather say so now than after the rotation turns.

Street Perspective

Debate: Is 20x the New Fair Multiple, or a Rotation Premium?

Bull view: AbbVie is a post-LOE compounder with mid-teens clean EPS growth, a 2031 data-protection floor on its largest asset, a dividend that keeps growing and a pipeline management calls undercalled. Defensive large-cap pharma is being re-rated as investors leave crowded technology names, and AbbVie deserves to trade at a premium within that group. Bull price targets above $300 were already circulating before the print.

Bear view: The multiple went from 14x to 20x 2026 ex-IPR&D earnings in six months while the earnings base moved about 1%. Almost all of the 2026 return has been multiple, and the October leg moved with the whole health-care sector. Rotations reverse, and when they do the stocks that re-rated most without estimate changes tend to give back the most.

Our take: The bear's arithmetic is right, and the bull's argument about quality is also right, which is why this is a valuation call and not a fundamental one. Our fair-value work credits the quarter's real improvements and rolls the earnings base forward, and still lands about 7% below the current price. Twenty times is a level we would pay for a business with visibility into 2030 growth beyond Skyrizi and Rinvoq. AbbVie is building that visibility, and it is not here yet.

Debate: Is the Pipeline Under-Modeled, or Already in the Price?

Bull view: Management named etentamig, Temab-A, zumilokibart and the three neuroscience franchises as above consensus. The quarter produced positive Phase 3 data for etentamig, Epkinly and lutikizumab, two breakthrough designations, two U.S. approvals and a closed deal. Long-term consensus has not caught up, and each readout adds value the Street is slow to model.

Bear view: Every named asset contributes meaningfully only from 2028. Several compete in crowded classes (myeloma bispecifics, ADCs, atopic dermatitis biologics), one is booked as a profit share, and the Apogee programs read out from late 2029. A stock at 18x 2027 earnings is already discounting some of this, and a management team arguing its stock is undervalued is not new information.

Our take: The bulls have the better of the data this quarter, and we credited part of it in fair value. But pipeline upside is the reason a stock should trade at a fair multiple rather than a discount. It is not a reason to pay a premium before the revenue exists. The bull case on the pipeline is the reason we are not more negative.

Debate: Can 2027 Deliver "Top-Tier Growth" Through Vraylar, Apogee and Humira?

Bull view: 2026 is on track for about 11% revenue growth and about 15% ex-IPR&D EPS growth. Next year adds subcutaneous induction, two Rinvoq dermatology launches, a full year of oral migraine growth and, from mid-year, etentamig. Management has beaten its own guide every quarter, and the Street's ~$16.28 is reachable.

Bear view: Next year also adds Vraylar's Medicare price, a full year of Apogee interest and eight Phase 3 programs' worth of spending, another year of Humira erosion, the Juvmo delay, and an aesthetics business that has not yet found its floor. The ~11% EPS growth implied by the Street is above the "top-tier" language management actually used, and the Q4 guide already sits below the Street.

Our take: We expect 2027 EPS growth in the high single digits to low double digits on a like-for-like basis, so we sit near the Street rather than below it. The issue is not a big miss. It is that at 18x the Street number the stock needs the February guide to land at or above it to hold the price, and management's initial guides are usually set to be beaten.

Model & Valuation Framework

Multiples on the same earnings year. At the $294.89 close, ABBV trades at about 20.1x the ex-IPR&D 2026 midpoint of $14.66 and 21.1x the as-published $13.97. At our Q2 note's $250.94, the same ex-IPR&D calculation gave 17.2x, and at the April upgrade 14.0x. On the 2027 Street number the stock trades at about 18.1x, against 15.5x at our Q2 note on the then-current ~$16.19 (15.4x on today's $16.28). However we cut it, the multiple has risen by roughly three turns in three months, and the earnings estimates under it have risen by less than 1%.

Fair value. In our Q2 note we anchored at roughly 16x the 2027 Street number. Rolling that forward one quarter, we now apply the multiple to a twelve-month-forward blend of three-quarters 2027 (about $16.28) and one-quarter 2028 (about $17.83, a thinner estimate set with a wide range), or about $16.67. We also raise the multiple to 16.5x from 16x to credit what genuinely improved: oncology back to growth, the Botox ruling, two U.S. approvals, a resubmission date, positive Phase 3 data in four programs, and a dividend raise. The result is a fair-value anchor of about $275, up from about $258, with a base range of about $258 to $292 (15.5x to 17.5x). Our new anchor sits about 10% above the $250.94 price our Q2 note called fair; that is as far as the evidence moves it. The anchor equals about 16.9x the 2027 Street number.

Scenarios. A bull case, with the February guide above the Street, aesthetics inflecting as the guide implies, the Botox ruling upheld and the sector premium persisting, supports 18x to 18.5x the forward blend, or about $300 to $308. From $294.89 that is roughly 2% to 5% of price plus a 2.5% yield, about a market-like return. A bear case, with a 2027 guide below the Street (a forward blend nearer $16.0) and the multiple returning to 15x as the rotation fades, supports about $240, roughly 19% below the current price. The base case, about $275, implies roughly 7% of price downside, or about −4% total return including the yield. Our bull case delivers about what we would expect from the market; the base and bear cases trail it.

Thesis Scorecard Post-Earnings

We carry forward the pillars established at our August 2025 initiation and graded through Q2 2026, and grade each against the Q3 2026 evidence as of November 1, 2026. We also grade, verbatim, the rating conditions published in our Q2 note on August 1.

Overall: The operating thesis is stronger than at our Q2 note. All four bull pillars hold, Bear 3 (oncology) and Bear 5 (balance sheet) eased, and Bear 4 (policy) improved on the Botox ruling. The only pillar that deteriorated on the numbers was aesthetics, which is too small to drive the stock. What changed decisively is Bear 1. At Q2 valuation was the reason for a Hold; this quarter it is binding enough to move the rating on its own, because the price moved 17.5% while the earnings base moved 0.8%.

Action: Downgrading to Underperform from Hold, with moderate conviction. In our Q2 note we wrote that we would move lower "only on an operational crack in immunology." That condition has not been met; immunology accelerated, and we are not going to argue that it has. We are moving anyway, and the reason is the one the Q2 note itself rested on: the rating was a valuation call, set when the stock sat about 3% below our fair value. It now sits about 7% above a fair value we have already raised, and at roughly our bull case. Holding to that sentence at this price would mean keeping a Hold whose expected return, about −4% including the dividend, we expect to trail the market. That would be using our own wording to avoid the conclusion our framework gives. We publish the conditions under which we would reverse this. We would return to Hold on a pullback toward about $265, where the expected return including the dividend is again roughly in line with the market. A 2027 guide in February with ex-IPR&D EPS at or above about $16.75, roughly 3% above the current Street and above our own expectation, would lift our anchor to about $283. That narrows the gap but does not close it at today's price, so on its own it would not move the rating. We keep the Q2-note conditions for a return to Outperform. We would revisit sooner on an operational crack in immunology, which would lower fair value rather than raise it. Nothing in this quarter suggests one. This is a downgrade of the price, not of the company.